Development↦Safety↦Safety Documentation↦The Protocol
What is it? Why is it important?
The study protocol is the document that describes the set-up and implementation of a study. The protocol should include:
- When and how (serious) adverse events (AEs) are collected, assessed, documented, reported and managed
- Safety outcomes, representing variables that are collected and monitored in order to assess the safety of the study, based on its intervention and/or procedures
The objective of collecting safety data during study conduct, and if applicable study follow-up, is to:
- Ensure study participants are protected from harm
- Maintain safety outcome oversight
- Detect the occurrence of new (serious) safety events (e.g. to be added to the product’s safety profile (e.g. IB for IMP/IMD, SmPC / PI for marketed MP, IFU for marketed MDs)
- Enable risk-benefit assessments on an ongoing basis
More
Safety outcomes should be clearly described in the protocol. They should:
- Cover study relevant safety events (e.g. laboratory parameters, vital signs)
- Have defined thresholds for abnormal values (e.g. acceptable values below or above given parameters)
- Describe causality relationship between AE and study intervention or procedures
- Reflect the dynamic change resulting from the study intervention or procedures (e.g. evolution of AE)
Based on study risk category, requirement for AE documentation varies. For study risk category:
- C: all AEs are documented in a standardised manner
- B: only AEs mentioned in the protocol or requested by authorities are documented
- A: no obligation of AE documentation exists
Still, irrespective of study risk category, the documentation and reporting of SAE is mandatory.
What do I need to do?
As a SP-INV describe in the study protocol:
- Safety objectives and outcome measures (e.g. laboratory parameters, particular AEs)
- The collection of adverse events and other safety related events
- Timeframe for safety data collection. Documentation starts once the participant has signed the ICF until:
- Study termination (e.g. last study participant at last study visit), or
- The end of some predefined safety follow-up period
- Procedures used for the assessment of safety events
- Procedures used for the documentation and reporting of serious safety events (e.g. EC/RA (e.g. Swissmedic), study SP-INV, marketing holder)
- In the event of blinded studies, a clear description regarding procedures on how to break the blind
- Study safety termination rules (e.g. based on safety analysis, DSMB support)
- The risk-benefit assessment of your study, and how its ratio supports the safe conduct of your study safety
Access the swissethics website for applicable and mandatory protocol templates.
For more information on this topic refer to Protocol and Quality & Risk in this study guide.
More
If a specific safety SOP describes how to handle safety during study conduct, the commitment to adhere to the SOP must be stated in the protocol.
Where can I get help?
Your local CTU↧ can support you with experienced staff regarding this topic
Basel, Departement Klinische Forschung, CTU, dkf.unibas.ch
Lugano, Clinical Trials Unit, CTU-EOC, www.ctueoc.ch
Bern, Clinical Trials Unit, CTU, www.ctu.unibe.ch
Geneva, Clinical Research Center, CRC, crc.hug.ch
Lausanne, Clinical Research Center, CRC, www.chuv.ch
St. Gallen, Clinical Trials Unit, CTU, www.kssg.ch
Zürich, Clinical Trials Center, CTC, www.usz.ch
External Links
Swissethics – see in particular
- Templates / Checklists
- Study protocols
References
ICH GCP E6(R2) – see in particular guidelines
- 1.44 Protocol definition
- 1.45 Protocol Amendment
- 2.5, 2.6 Principles
- 6 Clinical trial protocol and protocol amendment(s)
Declaration of Helsinki – see in particular principles
- 21-22 Protocol requirements
ISO 14155:2020 Medical device (access liable to cost) - see in particular sections and annex
- 6.4 Clinical Investigational Plan (CIP)
- Annex A CIP
Swiss Law
ClinO – see in particular articles
- Art. 19-20, 49, and 61 Categorisation
HRO – see in particular article
- Art. 7 Categorisation